Search | Clinical Trials Finder

Conditions: Hypertension
Interventions: valsartan + amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more

Conditions: Hypertension
Interventions: Aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Plasma Renin Activity
Interventions: Hydrochlorothiazide, Lisinopril, Amlodipine, metoprolol, lisinopril/hydrochlorothiazide; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions: Amlodipine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Obesity-Associated Insulin Resistance
Interventions: Moxonidine 0.2 MG, Amlodipine 5 MG; Drug
Lead sponsor: Italo Biaggioni; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Insulin Sensitivity, Aortic Compliance, Diastolic Function
Interventions: Aliskiren, Valsartan and Aliskiren, Amlodipine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Hypertension
Interventions: Amlodipine, Moxonidine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: Amlodipine, Olmesartan medoxomil plus amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 18
States / cities: Buena Park, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Hypertension, Vascular Stiffness, Aging
Interventions: Blood pressure treatment algorithm; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin

Conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions: Amlodipine, Nebivolol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healhty
Interventions: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg, Lotrel® Capsules 10 mg/20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hypertension
Interventions: Azilsartan Medoxomil and amlodipine, Amlodipine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 50
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more

Conditions: Focal Dystonia
Interventions: Amlodipine plus Botulinum toxin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions: Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Hypertension
Interventions: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 11,506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Essential Hypertension
Interventions: XOMA 985, Amlodipine Besylate, Perindopril Erbumine; Drug
Lead sponsor: Symplmed Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 48
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 45 more

Conditions: Erectile Dysfunction
Interventions: avanafil and enalapril, avanafil and amlodipine; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertension
Interventions: HCTZ + Amlodipine, Valsartan/HCTZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

Sympathetic Mechanisms in Obesity-Crossover Design

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

Arterial Stiffness and Blood Pressure

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Risk Reduction for Alzheimer's Disease

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Amlodipine Plus Botulinum Toxin for Focal Dystonia

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

Perindopril Amlodipine for the Treatment of Hypertension

Drug Interaction Study of Avanafil and Enalapril or Amlodipine

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg